Revenue
-700
2023 Q4 ·
Market value is not computed: this company has more than one listed security, and its filing does not count each class separately.
13 filing records in this dataset, filed from 2024-02-09 to 2026-11-13. Reported financial figures are available; chart coverage varies by period.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
Window: transactions dated on or after 2025-11-17.
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
-700
2023 Q4 ·
140,721%
2023 Q4 · %
-783 thousand
2023 Q4 ·
-893 thousand USD
2023 Q4 · USD
3258901 USD
9304701 shares
10.94% · 917 thousand shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
-10.1 million USD
2025-10-01 – 2026-09-30
-7.36 million USD
2025-10-01 – 2026-09-30
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-11-13.
Financial data available through: 2025-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Prior period
−USD 5.86 million
–
Current period
−USD 9.16 million
–
-9158734 − -5861335 = -3297399 USD
-5861335 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-9158734 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
−USD 8.51 million
–
Current period
−USD 6.5 million
–
-6502040 − -8505650 = 2003610 USD
-8505650 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-6502040 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
USD 396,451
–
Current period
USD 169,917
–
169917 − 396451 = -226534 USD
396451 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source169917 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | 70069 | 1866291 Derived | -1796222 | 242167 Derived | -2038389 | -1469582 Derived | Source
|
Amounts are exact, in USD.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Revenue | 70069 |
|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Year over year | No prior comparable period |
|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Operating margin | -2,563.5% |
|
| 2023 | Net margin | -2,909.1% |
|
| 2023 | Free cash flow margin | -2,097.3% |
|
Cash generated by the company’s normal business operations.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Operating cash flow | -1180870 |
|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Free cash flow | -1469582 |
|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Liabilities / assets | 110.8% |
|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Current assets / current liabilities | 0.5× |
|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 2.04 million Exact valueExact value: -2038389 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.18 million Exact valueExact value: -1180870 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 288,712 Exact valueExact value: 288712 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.47 million Calculation and evidence-1180870 − 288712 USD Exact free cash flow: -1469582 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 5.86 million Exact valueExact value: -5861335 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 8.51 million Exact valueExact value: -8505650 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 396,451 Exact valueExact value: 396451 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 8.9 million Calculation and evidence-8505650 − 396451 USD Exact free cash flow: -8902101 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 9.16 million Exact valueExact value: -9158734 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 6.5 million Exact valueExact value: -6502040 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 169,917 Exact valueExact value: 169917 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 6.67 million Calculation and evidence-6502040 − 169917 USD Exact free cash flow: -6671957 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
13 filings · 561 latest values · 561 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0002010788, 2010788, EXOZ, IZTC, edgar:2010788
Also known as EXOZYMES INC., INVIZYNE TECHNOLOGIES INC., Invizyne Technologies Inc